Clinical trial
Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic…
NCT00095732 · Anthera Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00095732 |
|---|---|
| Title | Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency |
| Official title | A Phase 2, Randomized, Double Blind, Parallel Dose Ranging Study of Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency |
| Lead sponsor | Anthera Pharmaceuticals, Industry |
| Collaborators | Cystic Fibrosis Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis, Pancreatic Insufficiency |
| Intervention type | Drug |
| Interventions | Liprotamase, Placebo |
| Enrollment | 129 |
| Start date | Jun 1, 2004 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Nov 9, 2004 |
| Last update posted | Oct 17, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: